Physician profile
Patrick Ratnasamy
NPI 1063403475
$3,298.45
in general payments reported to CMS, 2019-2025
36 companies · $924 in 2025
The $924 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $62.72 · 2023: $795 · 2024: $1,081 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,755 · Education: $45.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,755.04 |
| Education | $45.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $730.00 | 2023-2025 | |
| Glaxosmithkline, LLC. | $451.41 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $440.27 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $221.68 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $168.36 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $125.87 | 2019-2025 | |
| Ibsa Pharma INC. | $106.37 | 2023-2025 | Tirosint, Licart, Licart |
| Astrazeneca Pharmaceuticals LP | $88.31 | 2024-2025 | Farxiga, Airsupra |
| Amgen INC. | $87.89 | 2019-2025 | Otezla, Repatha, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.99 | 2024-2025 | Xifaxan |
| Sunovion Pharmaceuticals INC. | $79.74 | 2019 | |
| Sumitomo Pharma America, INC. | $62.33 | 2023-2025 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $54.66 | 2024-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Exact Sciences Corporation | $53.54 | 2024-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $52.04 | 2023-2025 | Dexcom G6 Transmitter |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $49.25 | 2024 | |
| Biofire Diagnostics, LLC | $48.41 | 2019 | |
| Boston Scientific Corporation | $46.21 | 2019 | |
| Phathom Pharmaceuticals, INC. | $39.67 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $34.45 | 2019-2020 | |
| Shield Therapeutics INC | $27.55 | 2024 | |
| Merck Sharp & Dohme LLC | $26.93 | 2019 | |
| Strongbridge US INC. | $19.50 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.53 | 2024 | |
| Amarin Pharma, INC. | $18.26 | 2020 | |
| Astellas Pharma US INC | $17.72 | 2023 | Myrbetriq |
| Inspire Medical Systems, INC. | $17.38 | 2023 | Inspire |
| Tactile Systems Technology INC | $16.04 | 2023 | Entre Plus, Flexitouch Plus |
| Esperion Therapeutics, INC. | $15.32 | 2025 | Nexletol |
| Lundbeck LLC | $14.88 | 2023 | Rexulti |
| Cequr Corporation | $14.40 | 2024 | Cequr Simplicity |
| Acadia Pharmaceuticals INC | $14.28 | 2023 | Nuplazid |
| Alnylam Pharmaceuticals INC. | $14.09 | 2023 | Onpattro |
| Watermark Medical, INC. | $13.69 | 2024 | |
| Idorsia Pharmaceuticals US INC | $12.92 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $11.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Ratnasamy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.